Clinical trial
Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy
NCT00336856 · University of Pittsburgh, Other · Completed
Key facts
| NCT number | NCT00336856 |
|---|---|
| Title | Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy |
| Official title | A Phase 2 Study of Irinotecan and Cetuximab on an Every 2 Week Schedule, as Second Line Therapy in Patients With Advanced Colorectal Cancer |
| Lead sponsor | University of Pittsburgh, Other |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colon Cancer, Rectum Cancer |
| Intervention type | Drug |
| Interventions | Cetuximab, Irinotecan |
| Enrollment | 35 |
| Start date | Jun 1, 2006 |
| Primary completion | Jun 1, 2011 |
| Completion | Jun 1, 2011 |
| First posted | Jun 14, 2006 |
| Last update posted | Jul 12, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: